Of those newly eligible under 2021 criteria, 2,063,840 were aged 50 to 54 years and 4,020,879 had 20 to 29-pack-year smoking history

Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab

Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy

For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery

HFJV under general anesthesia as safe as spontaneous respiration under moderate sedation for percutaneous lung ablation

Increased radiation with SABR boost seems to enhance local control but with reduced overall survival at highest dose

However, few individuals with newly diagnosed lung cancer engage in daily moderate-to-vigorous physical activity